Company / Free Cash Flow
Xenon Pharmaceuticals Inc. Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$279.9M
FY2025
5-year range
-$279.9M / -$71.6M
FY2021-FY2025
Trend
-51.7%
vs FY2024
Sector context
#166 of 194
Health Care
What the data says
Xenon Pharmaceuticals Inc.'s free cash flow of -$280M is lower than 86% of companies in the Health Care sector (FY2025). Free Cash Flow has declined for 6 consecutive years, from -$6M in FY2019 to -$280M in FY2025.
Based on SEC 10-K filings.
-$280M in FY2025.
Declined from -$157M to -$280M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 14% in Health CareTop 86% of 194This company -$279.9M Sector average $470.6M
▼
-159.5% below sector average
Key checks
Key Insights
- Xenon Pharmaceuticals Inc.'s free cash flow has declined for 6 consecutive years.
- In FY2025, free cash flow decreased 51.7% year-over-year.
- Ranks #166 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.51 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$279.9M | -51.7% |
| FY2024 | -$184.5M | -17.7% |
| FY2023 | -$156.7M | -50.8% |
| FY2022 | -$103.9M | -45.2% |
| FY2021 | -$71.6M | -41.0% |
| FY2020 | -$50.8M | -752.6% |
| FY2019 | -$6.0M | +83.1% |
| FY2018 | -$35.2M | -88.9% |
| FY2017 | -$18.7M | +6.0% |
| FY2016 | -$19.8M | -6.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026